http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103710371-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0331 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4747 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0278 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 |
| filingDate | 2006-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103710371-B |
| titleOfInvention | The suppression of B cell apoptosis in the transgenic animal of expression Humanized immunoglobulin |
| abstract | The application is related to the suppression of B cell apoptosis in the transgenic animal express Humanized immunoglobulin.The invention provides improving the new method of the immunoglobulin expression in non-human transgenic animal.For example, the invention provides improving through genetically engineered and express the method that the Humanized immunoglobulin in or several people's or humanized immunoglobulin transgene seat animal generates.This can be rabbit bcl 2 by overexpression inhibitors of apoptosis specific in the B cell of animal（Its expression is driven by B cell specificity promoter）, thus strengthen the survival of B cell carrying out.The invention further relates to Selective long-range DEPT exogenous B cell namely expresses the method that the survival of the B cell of any immunoglobulin transgene locus surpasses the not survival of the endogenous B cells of express transgenic locus.Selectivity is realized by only expressing inhibitors of apoptosis in exogenous B cell, that is, by being coupled together the expression of foreign immunologic globulin with inhibitors of apoptosis expression.This later approach allows to improve coded by transgenic（One or more）The expression of product and generate and surpass the immunoglobulin of the endogenous generation of transgenic animal.Present invention also offers new inhibitors of apoptosis, rabbit bcl 2. |
| priorityDate | 2005-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 420.